TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06416618

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical
Description: Surgical group: After osteosynthesis, they will be provided with a sling and swathe immediately after the surgery. From the first postoperative day, only the sling will be used. Two weeks postoperatively, patients will undergo clinical and radiological follow-up in the outpatient clinic. They will be referred to post-operative rehabilitation in the municipalities. At 12 weeks postoperatively, patients will have another clinical and radiological follow-up. This is the current standard care for surgical treatment with a plate or intramedullary nail.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non surgical
Description: Non-surgical group: Patients in the non-surgical group will be offered an optional sling for comfort for an additional 1-2 weeks at their first visit, 10-14 days post-injury. Patients will be referred to rehabilitation in the municipalities. At week 6 post-injury, all patients will undergo clinical and radiological follow-up. This represents the current standard care for non-surgical treatment of displaced PHF at the departments.
Study: NCT04579120

Intervention type: DRUG
Intervention: [11C]-Pittsburgh Compound B ([11C]PiB)
Description: A dosage range between 6.0 - 20.0 mCi (222-740 MBq) is planned for \[11C\] PIB. A PET-certified medical professional will prepare and administer the \[11C\] PIB tracer. Prior to the administration, the dosage will be assayed in a dose calibrator and diluted with 0.9% sodium chloride (normal saline) up to a total 20 mL syringe volume. Participants will receive a maximum intravenous bolus injection of 20.0 mCi of \[11C\] PIB followed by a 10 mL 0.9% sodium chloride (normal saline) flush.
Study: NCT05364177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-Pentixather
Description: After intravenous injection of 68Ga-pentixather, PET/CT scan will be performed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-Pentixafor
Description: After intravenous injection of 68Ga-pentixafor, PET/CT scan will be performed.
Study: NCT05553444

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management intervention
Description: The procedure will be based on the A - B - A'/B' design. After recruitment, patients will attend an initial session with CLS where written and oral information about the study will be provided. In this study, the A phase will serve as baseline to establish fluctuation in pain intensity prior to initiating the treatment.~During phase A, patients will be assessed every day for a minimum of 8 days and maximum of 14 days.~During phase B, CLS will facilitate the intervention based on the initial session, pain levels during phase A and the patients' goals. During phase B, patients will attend a 1-hour weekly session over 6 weeks.~During phase A', the participants will be followed weekly for 12 weeks. During the phase A', participants will not receive treatment.~Phase B' contains 3 x 1 hour criterion-based booster sessions which are delivered over 3 consecutive weeks.
Study: NCT06345235

Intervention type: DIAGNOSTIC_TEST
Intervention: blood test
Description: Assessment of the association of new biomarkers (GDF15, ST2, galectin-3, TIMP-1, MMP-9, NfL) and plasma prothrombotic potential in groups 1, 2, 3

Intervention type: DIAGNOSTIC_TEST
Intervention: blood test
Description: Assessment of the association of new biomarkers (GDF15, ST2, galectin-3, TIMP-1, MMP-9, NfL) and plasma prothrombotic potential in groups 1, 2, 3

Intervention type: DIAGNOSTIC_TEST
Intervention: blood test
Description: Assessment of the association of new biomarkers (GDF15, ST2, galectin-3, TIMP-1, MMP-9, NfL) and plasma prothrombotic potential in groups 1, 2, 3
Study: NCT05226390

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-SARS-2-ST
Description: In this trial MVA-SARS-2-ST will be used. Each vial contains 1 x 107 IU/dose MVA-SARS-2-ST in 0.5 mL as active ingredient. The solution will be used for nebulization and direct administration to the respiratory tract.
Study: NCT05444803

Intervention type: OTHER
Group type: OTHER
Intervention: femoral nerve block
Description: Patients will be performed a femoral nerve block using bupivacaine thirty minutes before the performing of spinal block.

Intervention type: OTHER
Group type: OTHER
Intervention: peri-capsular nerve group block
Description: Patients will be performed a peri-capsular nerve group block using bupivacaine thirty minutes before the performing of spinal block.
Study: NCT05545306

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: +150% of energy balance requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat
Description: +150% of energy balance requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: +150% of energy balance requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat
Description: +150% of energy balance requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: +150% of energy balance requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat
Description: +150% of energy balance requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat
Study: NCT05485662

Intervention type: OTHER
Group type: OTHER
Intervention: Hydroxyapatite toothpaste
Description: 10% Hydroxyapatite toothpaste

Intervention type: OTHER
Group type: OTHER
Intervention: Sodium Fluoride Toothpaste
Description: 1450 parts per million sodium fluoride toothpaste
Study: NCT06175364

Intervention type: OTHER
Group type: OTHER
Intervention: Health Professionals in the Field of Orthotics Prosthetics
Description: Three data collection tools will be used as data collection methods for the research. These data collection tools; demographic information form, Health Sciences Evidence-Based Practice Survey and Information Literacy Self-Efficacy Scale.
Study: NCT06307288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: minocycline
Description: The patient was treated with oral minocycline, 50mg each time, once a day, for 12 weeks.
Study: NCT04914416

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T3
Description: Verum T3 is a 11500AAIU/g white kidney bean extract. Daily dosage is 565 mg in 3 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Verum T4
Description: Verum T4 is a 17500AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T4
Description: Verum T4 is a 17500AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T4
Description: Verum T4 is a 17500AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules
Study: NCT06307288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: minocycline
Description: The patient was treated with oral minocycline, 50mg each time, once a day, for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranilast
Description: The patient was treated with oral tranilast, 0.1g each time, three times a day, for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranilast
Description: The patient was treated with oral tranilast, 0.1g each time, three times a day, for 12 weeks.
Study: NCT06428539

Intervention type: DIAGNOSTIC_TEST
Intervention: T-reg cells
Description: laboratory test

Intervention type: DIAGNOSTIC_TEST
Intervention: T-reg cells
Description: laboratory test

Intervention type: DIAGNOSTIC_TEST
Intervention: T-reg cells
Description: laboratory test
Study: NCT05017935

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal Denervation
Description: Renal angiogram and renal denervation (Paradise ultrasound Renal Denervation System)
Study: NCT06441591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinpocetine
Description: Vinca derivative of apovincamine, phosphodiestrase 1 inhibitor, sodium-gated voltage channel
Study: NCT05545306

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: -25% of energy balance requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat
Description: -25% of energy balance (EB) requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat
Study: NCT06441591

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard Therapy
Description: Anti-hypertensive and anti-diabetic medications according to the the institution's protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Therapy
Description: Anti-hypertensive and anti-diabetic medications according to the the institution's protocol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Starch-filled capsules, matching those of the intervention
Study: NCT05582343

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MINDBODYSTRONG™
Description: Digitalized MINDBODYSTRONG™ is designed for self-paced weekly use via an online platform.~MINDBODYSTRONG© Session Content~1. Thinking, feeling, \& behaving, The ABCs of CBT, Mindfulness Skills Building: Positive self-talk/The ABCs~2. Self-esteem \& positive self-talk, Intentional gratitude, Managing change Skills building: Self-esteem \& positive self-talk~3. Stress, Healthy coping, Abdominal breathing Skills Building: Managing stress~4. Problem solving, Setting goals, Steps to problem solving Skills building: Strategies to overcoming barriers~5. Dealing w/ emotions in healthy ways, Using guided imagery, Coping strategies, Effective communication Skills building: Dealing with emotions~6. Coping w/ stressful situations/valuable sleep Skills building: Coping w/ stressful situations~7. Distress tolerance \& added emotional regulation skills Skills bulding: RAIN practice, Self-love skill, Distracting using ACCEPTS~8. Putting it all together for a healthy YOU!
Study: NCT04882254

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Normothermic machine perfusion
Description: Additional 2h of normothermic machine perfusion of the donor kidney with a red cell based perfusate.
Study: NCT05730920

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: IV Methadone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (LB, Exparel)
Description: LB and bupivacaine hydrochloride via erector spinae plane blocks
Study: NCT05545306

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: -25% of energy balance requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat
Description: -25% of energy balance (EB) requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: -25% of energy balance requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat
Description: -25% of energy balance (EB) requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: -25% of energy balance requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat
Description: -25% of energy balance (EB) requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: -25% of energy balance requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat
Description: -25% of energy balance (EB) requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: +150% of dietary requirements, 51% of the calories from carbohydrates, 46%, from fat and 3% from protein
Description: +150% of energy balance requirements with low protein macronutrient balance of 51% of the calories from carbohydrates, 46%, from fat and 3% from protein.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: +150% of dietary requirements, 51% of the calories from carbohydrates, 46%, from fat and 3% from protein
Description: +150% of energy balance requirements with low protein macronutrient balance of 51% of the calories from carbohydrates, 46%, from fat and 3% from protein.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: +150% of dietary requirements, 51% of the calories from carbohydrates, 46%, from fat and 3% from protein
Description: +150% of energy balance requirements with low protein macronutrient balance of 51% of the calories from carbohydrates, 46%, from fat and 3% from protein.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: +150% of dietary requirements, 51% of the calories from carbohydrates, 46%, from fat and 3% from protein
Description: +150% of energy balance requirements with low protein macronutrient balance of 51% of the calories from carbohydrates, 46%, from fat and 3% from protein.
Study: NCT06143202

Intervention type: DEVICE
Intervention: Freestyle Libre 3 Continuous Glucose Monitor
Description: Pediatric participants will wear a blinded Freestyle Libre 3 CGM. Data will not be available, and therefore the device will not be used to modify medical management.
Study: NCT06212492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMBAs
Description: Early and systematic use of NMBAs

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prone positioning
Description: Early and systematic use of prone positioning

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prone positioning
Description: Early and systematic use of prone positioning
Study: NCT06562920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adebrelimab and chemotherapy
Description: 3 cycles of adebrelimab combined with chemotherapy and concurrent SBRT, and undergo surgery within 4-6 weeks after treatment.
Study: NCT05545306

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: +150% of dietary requirements, 51% of the calories from carbohydrates, 46%, from fat and 3% from protein
Description: +150% of energy balance requirements with low protein macronutrient balance of 51% of the calories from carbohydrates, 46%, from fat and 3% from protein.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: +150% of dietary requirements, 51% of the calories from carbohydrates, 46%, from fat and 3% from protein
Description: +150% of energy balance requirements with low protein macronutrient balance of 51% of the calories from carbohydrates, 46%, from fat and 3% from protein.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: +150% of dietary requirements, 51% of the calories from carbohydrates, 46%, from fat and 3% from protein
Description: +150% of energy balance requirements with low protein macronutrient balance of 51% of the calories from carbohydrates, 46%, from fat and 3% from protein.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: +150% of dietary requirements, 51% of the calories from carbohydrates, 46%, from fat and 3% from protein
Description: +150% of energy balance requirements with low protein macronutrient balance of 51% of the calories from carbohydrates, 46%, from fat and 3% from protein.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: +150% of dietary requirements, 51% of the calories from carbohydrates, 46%, from fat and 3% from protein
Description: +150% of energy balance requirements with low protein macronutrient balance of 51% of the calories from carbohydrates, 46%, from fat and 3% from protein.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: +150% of dietary requirements, 51% of the calories from carbohydrates, 46%, from fat and 3% from protein
Description: +150% of energy balance requirements with low protein macronutrient balance of 51% of the calories from carbohydrates, 46%, from fat and 3% from protein.
Study: NCT04902066

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Virtual Reality Therapy.
Description: Cognitive Behavioural Therapy augmented with Virtual Reality.
Study: NCT04914416

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T5
Description: Verum T5 is a 17500AAIU/g white kidney bean extract. Daily dosage is 371 mg in 3 capsules
Study: NCT04902066

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Cognitive Behavioural Therapy
Description: Traditional Cognitive Behavioural Therapy for psychosis.
Study: NCT04579120

Intervention type: DRUG
Intervention: [11C]-Pittsburgh Compound B ([11C]PiB)
Description: A dosage range between 6.0 - 20.0 mCi (222-740 MBq) is planned for \[11C\] PIB. A PET-certified medical professional will prepare and administer the \[11C\] PIB tracer. Prior to the administration, the dosage will be assayed in a dose calibrator and diluted with 0.9% sodium chloride (normal saline) up to a total 20 mL syringe volume. Participants will receive a maximum intravenous bolus injection of 20.0 mCi of \[11C\] PIB followed by a 10 mL 0.9% sodium chloride (normal saline) flush.

Intervention type: DRUG
Intervention: F 18 AV-1451 (Flortaucipir)
Description: A dosage range between 6.5 - 10.0 mCi (240-370MBq) is planned for \[18F\] AV-1451. A PET-certified medical professional will prepare and administer the \[18F\] AV-1451tracer. Prior to the administration, the dosage will be assayed in a dose calibrator. The volume of 18F-AV-1451 dose should not be adjusted by adding normal saline to the syringe. Participants will receive a maximum intravenous bolus injection of 10.0 mCi of \[18F\] AV-1451 followed by a 10 mL flush of 0.9% sodium chloride (normal saline).

Intervention type: DRUG
Intervention: F 18 AV-1451 (Flortaucipir)
Description: A dosage range between 6.5 - 10.0 mCi (240-370MBq) is planned for \[18F\] AV-1451. A PET-certified medical professional will prepare and administer the \[18F\] AV-1451tracer. Prior to the administration, the dosage will be assayed in a dose calibrator. The volume of 18F-AV-1451 dose should not be adjusted by adding normal saline to the syringe. Participants will receive a maximum intravenous bolus injection of 10.0 mCi of \[18F\] AV-1451 followed by a 10 mL flush of 0.9% sodium chloride (normal saline).
Study: NCT05174637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDA018-ADC
Description: FDA018-ADC will be administered via IV infusion on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1 and 8 of a 21-day cycle (Cycle 2 \~ Cycle 5) in dose escalation phase, and on Day 1 and 8 of a 21-day cycle(Cycle 1 \~ Cycle 6) in dose expansion phase, and Day 1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDA018-ADC
Description: FDA018-ADC will be administered via IV infusion on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1 and 8 of a 21-day cycle (Cycle 2 \~ Cycle 5) in dose escalation phase, and on Day 1 and 8 of a 21-day cycle(Cycle 1 \~ Cycle 6) in dose expansion phase, and Day 1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDA018-ADC
Description: FDA018-ADC will be administered via IV infusion on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1 and 8 of a 21-day cycle (Cycle 2 \~ Cycle 5) in dose escalation phase, and on Day 1 and 8 of a 21-day cycle(Cycle 1 \~ Cycle 6) in dose expansion phase, and Day 1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDA018-ADC
Description: FDA018-ADC will be administered via IV infusion on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1 and 8 of a 21-day cycle (Cycle 2 \~ Cycle 5) in dose escalation phase, and on Day 1 and 8 of a 21-day cycle(Cycle 1 \~ Cycle 6) in dose expansion phase, and Day 1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDA018-ADC
Description: FDA018-ADC will be administered via IV infusion on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1 and 8 of a 21-day cycle (Cycle 2 \~ Cycle 5) in dose escalation phase, and on Day 1 and 8 of a 21-day cycle(Cycle 1 \~ Cycle 6) in dose expansion phase, and Day 1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.
Study: NCT04293848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibroacoustic therapy
Description: listening to low-frequency sound of 40 Hz with biorhythmic sequential modulation combined to music

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Only music (no vibrations)
Description: listening to music, no vibrations
Study: NCT06480110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel + Ebastine
Description: Ebastine is administered once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: docetaxel every three weeks
Study: NCT06434740

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy，SBRT
Description: The enrolled subjects will receive SBRT treatment for lung metastases.The dose segmentation is 10Gy/f, with a total dose of 50Gy/5f, once every other day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Puterizumab
Description: Within 7-14 days after SBRT, Puterizumab should be used (dosage: recommended dosage of 200mg, intravenous infusion, infusion time of 60 minutes (± 15 minutes), once every 3 weeks (Q3W), for 6-8 months or intolerable toxicity).
Study: NCT05859620

Intervention type: OTHER
Intervention: Patient assessment and follow-up
Description: There is no study-specific intervention. The investigators will record data generated by clinical activity before, during and after implementation of the PMI-screening. Follow-up data and the final PMI event adjudication will be the only data generated specifically for this study.

Intervention type: OTHER
Intervention: Patient assessment and follow-up
Description: There is no study-specific intervention. The investigators will record data generated by clinical activity before, during and after implementation of the PMI-screening. Follow-up data and the final PMI event adjudication will be the only data generated specifically for this study.